在土耳其群体中进行ABCA4变异查,该群体患有Stargardt病
Neslihan Sinim Kahraman1, Büşra Özgüç Çalışkan2, Nefise Kandemir3
1Department of Ophthalmology, Acibadem Hospital, İstanbul, Türkiye.
Ophthalmic genetics
|February 18, 2024
概括
这项研究在Stargardt病患者中确定了ABCA4基因变异,发现了两种新型变异和常见的致病突变. 需要对更大的队列进行进一步的研究,以了解Stargardt病的基因型-表型相关性.
科学领域:
- 眼科医生 眼科 眼科
- 遗传学 是一个遗传学.
- 医学研究 医学研究
背景情况:
- 斯塔格特病是一种常见的遗传性黄斑变质症.
- ABCA4基因突变是斯塔格特病的主要原因.
- 了解ABCA4变体对于诊断和潜在治疗至关重要.
研究的目的:
- 为了评估ABCA4变异的频谱在一个队列的土耳其患者与Stargardt病.
- 为了识别新的ABCA4变异和常见的致病突变.
- 为了将遗传发现与临床表现相关联.
主要方法:
- 对Stargardt病患者的回顾性分析.
- 记录临床数据,包括视敏度和成像.
- 对ABCA4基因进行查,以检测具有至少两种已识别突变的患者的变异.
主要成果:
- 分析了27名患有Stargardt病和ABCA4变体的患者.
- 在54个ABCA4等位基因中发现了30种不同的变异.
- 确定了两个新型变异 (c.3855_3856dup,c.1554+3_1554+4del),以及常见的突变,如c.5882G>A p.
结论:
- 在土耳其Stargardt疾病队列中发现了两种新的ABCA4变异.
- 在这个群体中,c.52C>T p.(Arg18Trp) 变异是最常见的致病突变.
- 需要进行更大规模的研究来充分描述ABCA4变异及其表型影响.
更多相关视频
05:58Digital Polymerase Chain Reaction Assay for the Genetic Variation in a Sporadic Familial Adenomatous Polyposis Patient Using the Chip-in-a-tube Format
Published on: August 20, 2018
10.9K
09:22Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
5.5K
相关概念视频
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
